 |
 Video: What is a Stock Split?
|
|
|
| Cyteir Therapeutics, Inc. is a clinical-stage biotechnology company. Co. is focused on developing of CYT-0851, an oral investigational drug candidate that inhibits monocarboxylate transporters. CYT-0851 is an investigational monocarboxylate transporter inhibitor (MCT) inhibitor, initially evaluated in a phase I/II study to treat patients with hematologic malignancies and solid tumors as a monotherapy and in combination with standard of care therapies. Inhibiting MCT function in glycolytic cancer cells leads to an accumulation of intracellular lactate that impairs glycolysis and inhibits tumor cell growth, making MCTs an attractive target for cancer therapy. According to our CYT split history records, Cyteir Therapeutics has had 2 splits. | |
|
Cyteir Therapeutics (CYT) has 2 splits in our CYT split history database. The first split for CYT took place on July 24, 1996. This was a 3 for 1
split, meaning for each share of CYT owned pre-split, the shareholder now owned 3 shares. For example, a 1000 share position pre-split, became a 3000 share position following the split. CYT's second split took place on September 18, 2014. This was a 2 for 1 split, meaning for each share of CYT owned pre-split, the shareholder now owned 2 shares. For example, a 3000 share position pre-split, became a 6000 share position following the split.
When a company such as Cyteir Therapeutics splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business.
Looking at the CYT split history from start to finish, an original position size of 1000 shares would have turned into 6000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Cyteir Therapeutics shares, starting with a $10,000 purchase of CYT, presented on a split-history-adjusted basis factoring in the complete CYT split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
06/21/2021 |
|
| End date: |
03/15/2024 |
|
| Start price/share: |
$17.32 |
|
| End price/share: |
$3.02 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-82.56% |
|
| Average Annual Total Return: |
-47.21% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$1,743.36 |
|
| Years: |
2.73 |
|
|
|
| Date |
Ratio |
| 07/24/1996 | 3 for 1
| | 09/18/2014 | 2 for 1 |
|
|
Free CYT Email Alerts:
